XML 39 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) - USD ($)
$ in Thousands
3 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Segment Reporting Information [Line Items]    
Revenue $ 51,480 $ 52,283
Revenue, % change (2.00%)  
Diagnostics [Member]    
Segment Reporting Information [Line Items]    
Revenue $ 36,665 37,490
Revenue, % change (2.00%)  
Diagnostics [Member] | Molecular Assays [Member]    
Segment Reporting Information [Line Items]    
Revenue $ 7,298 8,717
Revenue, % change (16.00%)  
Diagnostics [Member] | Immunoassays & Blood Chemistry Assays [Member]    
Segment Reporting Information [Line Items]    
Revenue $ 29,367 28,773
Revenue, % change 2.00%  
Life Science [Member]    
Segment Reporting Information [Line Items]    
Revenue $ 14,815 14,793
Life Science [Member] | Molecular Reagents [Member]    
Segment Reporting Information [Line Items]    
Revenue $ 6,589 5,688
Revenue, % change 16.00%  
Life Science [Member] | Immunological Reagents [Member]    
Segment Reporting Information [Line Items]    
Revenue $ 8,226 $ 9,105
Revenue, % change (10.00%)